Prospects Oncology Fund
FACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Ontario First investment strategy and have the potential to act as deal flow for the Compass Rose Fund. Prospects funding typically ranges between $50,000 and $200,000.
Prospects Fund Profile:
Typical Funding per Project | $50k to $200k, one-time payment |
Project Duration | Up to one year |
Eligibility | Ontario-based academic researchers and start-ups in the oncology space |
Type of Investment* | Grant-like with certain rights for FACIT |
Qualifying Investment Profile | Innovative technology not incremental advance; A clear path forward for commercialization; A discrete project with quantifiable outcomes tied to funding; Oncology-related and located in Ontario; Has Ontario IP or is likely to create it |
Main Goal of Investment | Funds should enable development and/or market research to advance the technology and support or ascertain proof-of-concept |
“We are at a pivotal moment in our company’s development and are fortunate to benefit from FACIT’s continued support and resources which are fuelling Xpan’s growth and accelerating our journey to commercialization”
Mr. Zaid Atto, Founder and CEO of Xpan. (2020)
How to apply:
The Prospects Fund has two independent application rounds per year, with pre-submission forms accepted by:
- March 31
- September 30
Late applications will not be considered. Selected applicants will then be invited to prepare a Prospects funding package which is subject to due diligence by FACIT and final approval by FACIT’s Board of Directors.
Projects Recently Funded By The Prospects Oncology Fund
We stand behind these promising made-in-Ontario innovations.
SEARCH FILTERS:
Innovation Type
Cancer Type
Current Funding Stage
FACIT Fund
SEARCH BY KEYWORD(S)
SEARCH RESULTS:
OICR
Sunnybrook Research Institute
Hyivy Health
Point Surgical Inc.
OICR
HDAX Therapeutics
OICR
Air Microfluidic Systems Inc.
Tenomix
doctalk

Bridge7 Oncology
Replica Analytics (Aetion)
Multimagnetics Inc.
University of Toronto
Radiant Biotherapeutics
CTRL Therapeutics
Xpan Inc
OICR
Sunnybrook Research Institute
University of Toronto (Perturba)

Polumiros
Talon Pharmaceuticals
Notch Therapeutics
OICR
QurCan Therapeutics (formerly Nanology Labs)
16-Bit
DNAStack
Dalriada Therapeutics
KA Imaging
Radialis Medical
Ottawa Hospital Research Institute
OICR
Propellon Therapeutics Inc. (Triphase Accelerator)
Pattern Pharma (formerly Realist Pharma)
Talon Pharmaceuticals
Queen’s University
Fusion Pharmaceuticals Inc
Novera Therapeutics Inc.

FocusOnCare
Capnostics
Sunnybrook Research Institute
OICR
Sunnybrook Research Institute
Ziliomics
Sunnybrook Research Institute
OICR
Turnstone Biologics Inc
Fluorinov Pharma (Trillium)
OICR (Cellax)

XLV Diagnostics
Privacy Analytics (IQVIA)
Arrayus Technologies (formerly Harmonic Medical)
McMaster University

Triphase Accelerator Corporation
Kapplex
Xagenic

DLVR Therapeutics
